|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
Download
|
|
pTurboGFP-mito is a mammalian expression vector intended for green fluorescent labeling of mitochondria in living cells. The vector encodes green fluorescent protein TurboGFP (see reporter description) fused to mitochondrial targeting sequence (MTS) derived from the subunit VIII of human cytochrome C oxidase [Rizzuto et al., 1989; Rizzuto et al., 1995]. MTS is fused to the TurboGFP N-terminus.
Stably transfected HeLa cells expressing mitochondria-targeted TurboGFP.Image was kindly provided by Dr. Christian Petzelt (Marinpharm). |
TurboGFP codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al., 1996].
pTurboGFP-mito vector can be used as a source of TurboGFP-MTS hybrid sequence. The vector backbone contains unique restriction sites that permit its excision and further insertion into expression vector of choice.
Note: The plasmid DNA was isolated from dam+-methylated
The vector backbone contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in
Expression in mammalian cells
pTurboGFP-mito vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of the TurboGFP-MTS fusion in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Propagation in
Suitable host strains for propagation in
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
TurboGFP-mito fusion
Start codon (ATG): 597-599
Mitochondrial targeting sequence (MTS): 597-683
Start of TurboGFP coding sequence (ATG): 705-707
Stop codon: 1401-1403
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 1557-1562 & 1586-1591
mRNA 3' ends: 1595 & 1607
f1 single-strand DNA origin: 1654-2109
Bacterial promoter for expression of Kanr gene
-35 region: 2171-2176
-10 region: 2194-2199
Transcription start point: 2206
SV40 origin of replication: 2450-2585
SV40 early promoter
Enhancer (72-bp tandem repeats): 2283-2354 & 2355-2426
21-bp repeats: 2430-2450, 2451-2471 & 2473-2493
Early promoter element: 2506-2512
Major transcription start points: 2502, 2540, 2546 & 2551
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 2634-2636
Stop codon: 3426-3428
G->A mutation to remove Pst I site: 2816
C->A (Arg to Ser) mutation to remove BssH II site: 3162
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 3664-3669 & 3677-3682
pUC plasmid replication origin: 4013-4656
TurboGFP-related materials (also referred to as "Products") are intended for research use only. The Products are covered by U.S. Pat. 7,678,893; European Pat. 1576157; and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
Copyright 2002-2023 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |